Journal of Allergy and Clinical Immunology

Papers
(The H4-Index of Journal of Allergy and Clinical Immunology is 79. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan1477
Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19723
Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19517
Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2420
2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group408
Anaphylaxis—a 2020 practice parameter update, systematic review, and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) analysis394
Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials369
Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial343
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19270
Coronavirus disease 2019 in patients with inborn errors of immunity: An international study258
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells249
Single-cell transcriptome analysis of human skin identifies novel fibroblast subpopulation and enrichment of immune subsets in atopic dermatitis248
A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia247
Eosinophil responses during COVID-19 infections and coronavirus vaccination239
Longitudinal hematologic and immunologic variations associated with the progression of COVID-19 patients in China232
Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial228
Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19227
Type I IFN immunoprofiling in COVID-19 patients214
Allergic disorders and susceptibility to and severity of COVID-19: A nationwide cohort study202
Complement activation in patients with COVID-19: A novel therapeutic target199
Influence of immune aging on vaccine responses175
COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience175
The role of IL-6 and other mediators in the cytokine storm associated with SARS-CoV-2 infection173
EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management168
Association of asthma and its genetic predisposition with the risk of severe COVID-19162
Epithelial barriers in allergy and asthma160
Environmental factors in epithelial barrier dysfunction157
IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study154
Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity148
IL-6–based mortality risk model for hospitalized patients with COVID-19145
Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: A randomized, placebo-controlled trial143
Astegolimab (anti-ST2) efficacy and safety in adults with severe asthma: A randomized clinical trial141
An expert consensus framework for asthma remission as a treatment goal139
Biomarkers in atopic dermatitis—a review on behalf of the International Eczema Council138
Rhinitis 2020: A practice parameter update136
Heritable risk for severe anaphylaxis associated with increased α-tryptase–encoding germline copy number at TPSAB1131
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19129
Drug allergy: A 2022 practice parameter update122
Air pollution, racial disparities, and COVID-19 mortality121
Factors associated with adverse COVID-19 outcomes in patients with psoriasis—insights from a global registry–based study119
JAK inhibitors in the treatment of atopic dermatitis119
Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines112
New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation110
Safety and efficacy of early high-dose IV anakinra in severe COVID-19 lung disease109
Single-cell transcriptomics combined with interstitial fluid proteomics defines cell type–specific immune regulation in atopic dermatitis108
Inhaled corticosteroids downregulate the SARS-CoV-2 receptor ACE2 in COPD through suppression of type I interferon108
Food allergy across the globe105
Asthma among hospitalized patients with COVID-19 and related outcomes105
Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis103
Biologics for chronic rhinosinusitis with nasal polyps103
Autoimmune bullous skin diseases, pemphigus and pemphigoid102
Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial100
Asthma-associated risk for COVID-19 development100
Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score98
The sputum microbiome, airway inflammation, and mortality in chronic obstructive pulmonary disease97
Untargeted metabolomic profiling identifies disease-specific signatures in food allergy and asthma96
Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses96
Biomarkers of severity and threshold of allergic reactions during oral peanut challenges96
Adult-onset autoinflammation caused by somatic mutations in UBA1: A Dutch case series of patients with VEXAS95
Cutaneous barrier dysfunction in allergic diseases94
COVID-19: Unanswered questions on immune response and pathogenesis89
Genotype and functional correlates of disease phenotype in deficiency of adenosine deaminase 2 (DADA2)89
Obesity and asthma89
Regulating T-cell differentiation through the polyamine spermidine87
Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS186
Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: A systematic review and network meta-analysis86
Formation of nasal polyps: The roles of innate type 2 inflammation and deposition of fibrin86
Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype85
Staphylococcus epidermidis protease EcpA can be a deleterious component of the skin microbiome in atopic dermatitis84
Anakinra combined with methylprednisolone in patients with severe COVID-19 pneumonia and hyperinflammation: An observational cohort study83
Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach82
On the cause and consequences of IgE to galactose-α-1,3-galactose: A report from the National Institute of Allergy and Infectious Diseases Workshop on Understanding IgE-Mediated Mammalian Meat Allergy82
Clinical Olfactory Working Group consensus statement on the treatment of postinfectious olfactory dysfunction82
Sustained successful peanut oral immunotherapy associated with low basophil activation and peanut-specific IgE81
Health disparities in allergic and immunologic conditions in racial and ethnic underserved populations: A Work Group Report of the AAAAI Committee on the Underserved81
SARS-CoV-2 antibody testing—questions to be asked81
Defining challenge-proven coexistent nut and sesame seed allergy: A prospective multicenter European study80
Randomized trial of early infant formula introduction to prevent cow’s milk allergy79
Mechanisms underlying genetic susceptibility to multisystem inflammatory syndrome in children (MIS-C)79
Clinical testing for COVID-1979
0.034950017929077